[Elsevier] Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial |
|
This post will be closed automatically in 2026-08-29 18:13
Reward20points
|
post
reply
points
2771
20
Human serum albumin-imprinted polymers with high capacity and selectivity for abundant protein depletion
10
Self-assembled ※3D-stereoscopic printing-like§ PANI-based porous carbon aerogels for high-efficiency CO2 adsorption
10
Optimality conditions for nonsmooth vector interval-valued bilevel optimization problems in terms of tangential subdifferentials
10
Archean eolian dynamics, deposits, and indicators of other weather phenomena: Lessons from Earth and Mars
10
Physical activity, fitness, and longevity
